Generic options now available for some MS treatments
5 June 2019
From 1 June 2019, generic medications for MS may become available for disease modifying therapies in Australia – in particular for teriflunomide (Aubagio).
From 1 June 2019, generic medications for MS may become available for disease modifying therapies in Australia – in particular for teriflunomide (Aubagio).
Monoclonal antibodies or ‘mabs’ for short, are the secret agents revolutionising modern medicine and being used to treat various conditions including MS.
New Australian research has found a link between EBV infection and MS risk genes which will enhance understanding of the role of EBV at a cellular level.
Study shows significant overlap between vitamin D ‘super enhancers’ (genetic enhancers which proteins bind to when vitamin D is present) and MS risk genes.
The Federal Government has announced a $10 million MS funding boost for Menzies Institute for Medical Research for its collaborative research program.
The European medical regulatory body has announced a safety review of alemtuzumab (Lemtrada), an approved medication for relapsing
Brain tissue can be split into two kinds, grey matter (mainly nerve cell bodies and branching connections) and
We met at an MS Research Australia engagement session as part of the exciting Stop and Reverse MS
Non-processed red meat consumption has been linked with reduced risk of MS according to a new study suggesting it may have a protective effect against developing MS.